starting to get noticed, page-7

re: nowhere man ... G'day there nowhere man!

Been in & out of the F/P's a few times over the last six months & currently have exposure for a s/t momentum trade to see where this rally leads.

Am personally very bullish on the potential of SLA relative to market cap vs markets & patent & will probably look at a long position via the SLACB once they resume trading & the dust settles.
I did the conversions with SLACA today, & was mighty tempted but alas ... had to go the liquidity!

Am I correct in assuming that if all contributions are made, the company will then have an additional cash injection of >A$770K visible on the next quarterly?
Nevertheless, a very interesting type of security!
Thanks for your posts & good luck!

Warm regards!
: )



********


Solagran Limited
Solagran Limited
ACN 002 592 396
Level 11
492 St Kilda Road
Melbourne 3004
Victoria
Australia
Tel 61 3 9820 2699
Fax 61 3 9820 3155
11 November, 2004
Company Announcement
Contributing Shares (SLACA)
Solagran Limited confirms details in regard to the $0.02 per share call on Contributing
Shares due on 30 November, 2004.
Any Contributing Shareholder who has not received a Call Payment Notice should contact
Computershare Investor Services Pty Limited on 1300 557 010.
SLACA Contributing Shares (paid to $0.01) will cease trading on ASX on 16 November,
2004.
The Contributing Shares (as paid to $0.03) will commence trading on a deferred settlement
basis under the new ASX Code of SLACB on 17 November, 2004.
The Share Registry will close off all transfers of SLACA Contributing Shares on 19
November, 2004.
The Record Date for the call is 23 November, 2004.
All Registered Holders of SLACA Contributing Shares on 23 November, 2004 should be
aware that if the call of $0.02 per Contributing Share is not paid by 30 November, 2004 then
all Contributing Shares with unpaid calls are forfeited for no value.
Peter Stedwell
Director
On behalf of the Board of Directors
Solagran Limited
Solagran Limited is an Australian company founded in 1995 with the objective of commercialising the
results of a research and development program that commenced in Russia in the 1930s, and which
has continued, uninterrupted, until the present day. The focus of the research program has been the
extraction and utilisation of the “live elements” of tree foliage. Solagran has collectively trademarked
these substances using the term Bioeffectives®.
Solagran’s technology permits it to obtain many different Bioeffectives from tree and plant sources.
One of the highest value Bioeffectives is a class of organic substances known as polyprenols.
Polyprenols are naturally occurring precursors of dolichol, which is found in all of the vital organs of
the human body, and which plays an essential role in cell metabolism and in supporting the immune
system.
Solagran has committed significant resources to the development and testing of Bioeffective R – a
Bioeffective comprising polyprenols. Experimental results suggest Bioeffective R has a very positive
impact on damaged liver cells.